MA40627A - Formulations stables de lipides et de liposomes - Google Patents

Formulations stables de lipides et de liposomes

Info

Publication number
MA40627A
MA40627A MA040627A MA40627A MA40627A MA 40627 A MA40627 A MA 40627A MA 040627 A MA040627 A MA 040627A MA 40627 A MA40627 A MA 40627A MA 40627 A MA40627 A MA 40627A
Authority
MA
Morocco
Prior art keywords
liposomes
lipids
stable formulations
formulations
methods
Prior art date
Application number
MA040627A
Other languages
English (en)
Inventor
Borquez Isaac Hernan Esparza
Heinrich Haas
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MA40627A publication Critical patent/MA40627A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations aqueuses de lipides et/ou de liposomes ayant une stabilité chimique accrue, des procédés de préparation de telles formulations aqueuses, ainsi que des kits les comprenant. La présente invention concerne en outre des procédés de préparation des compositions pharmaceutiques à base de lipides, des compositions pharmaceutiques préparées au moyen de tels procédés et des procédés permettant de stabiliser chimiquement des formulations aqueuses de lipides et/ou de l
MA040627A 2014-09-25 2015-09-17 Formulations stables de lipides et de liposomes MA40627A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/070503 WO2016045732A1 (fr) 2014-09-25 2014-09-25 Formulations stables de lipides et de liposomes

Publications (1)

Publication Number Publication Date
MA40627A true MA40627A (fr) 2016-03-31

Family

ID=51626523

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040627A MA40627A (fr) 2014-09-25 2015-09-17 Formulations stables de lipides et de liposomes

Country Status (17)

Country Link
US (2) US11173120B2 (fr)
EP (1) EP3197433A1 (fr)
JP (1) JP6703982B2 (fr)
KR (1) KR102264820B1 (fr)
CN (1) CN107072945B (fr)
AU (1) AU2015320980B2 (fr)
BR (1) BR112017005821B1 (fr)
CA (1) CA2960934C (fr)
IL (2) IL250991B (fr)
MA (1) MA40627A (fr)
MX (1) MX2017003794A (fr)
MY (1) MY184381A (fr)
NZ (1) NZ730368A (fr)
RU (1) RU2738060C2 (fr)
SG (1) SG11201702182YA (fr)
WO (2) WO2016045732A1 (fr)
ZA (1) ZA201701670B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016045732A1 (fr) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Formulations stables de lipides et de liposomes
SG11202002579SA (en) * 2017-10-20 2020-05-28 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
EP3892260A1 (fr) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Compositions immunostimulantes sur la base de liposomes avec les lipides zwitterioniques et cationiques
EP3901261A1 (fr) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Vaccin contre le coronavirus
EP4334943A1 (fr) 2021-05-04 2024-03-13 BioNTech SE Technologies de détection précoce de variants d'intérêt
KR20240042414A (ko) 2021-07-29 2024-04-02 비온테크 에스이 흑색종의 치료용 조성물 및 방법
CN114306244B (zh) * 2022-01-14 2023-04-07 苏州尔生生物医药有限公司 一种微米级脂质复合物及其制备和应用
WO2024002985A1 (fr) 2022-06-26 2024-01-04 BioNTech SE Vaccin contre le coronavirus

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816925A (en) * 1955-10-07 1957-12-17 Du Pont Diamines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4975964A (en) * 1989-06-27 1990-12-04 Hochstein Peter A Automatic turn off system
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DK0900380T3 (da) 1996-04-26 2003-11-03 Seed Capital Investments Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper
WO1998010748A1 (fr) 1996-09-13 1998-03-19 The School Of Pharmacy Liposomes
CA2217550A1 (fr) * 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Lipides cationiques pour therapie genique
EP0839912A1 (fr) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Clones infectieux de virus à ARN, vaccins et essais diagnostiques
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
WO1999024566A1 (fr) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Antigenes specifiques a une tumeur, procede de production et utilisation de ces antigenes pour assurer une immunisation et diagnostic
WO1999033500A2 (fr) * 1997-12-31 1999-07-08 Pharmasonics, Inc. Procedes, systemes et kits pour l'apport intravasculaire d'acides nucleiques
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
WO2000020029A1 (fr) 1998-10-05 2000-04-13 Genzyme Corporation Genes differemment exprimes dans des cellules cancereuses servant a la mise au point de vaccins contre le cancer
US9034329B2 (en) * 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US8617514B2 (en) * 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000067761A1 (fr) 1999-05-06 2000-11-16 Wake Forest University Compositions et procedes d'identification d'antigenes provoquant une reponse immunitaire
US7094423B1 (en) * 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
WO2001047959A2 (fr) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Molecules d'acides nucleiques isoles codant pour des antigenes associes au cancers, ces antigenes et leur utilisation
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
KR100838507B1 (ko) 1999-12-28 2008-06-17 에피뮨 인코포레이티드 최적화된 미니유전자 및 이에 의해 암호화된 펩타이드
JP2004530629A (ja) 2000-06-07 2004-10-07 バイオシネクサス インコーポレーテッド 免疫刺激ｒｎａ／ｄｎａハイブリッド分子
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP1604688B1 (fr) 2001-06-05 2010-02-03 CureVac GmbH ARNm stabilisé codant pour un antigène tumoral avec un contenu G/C augmenté
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
DK1512014T3 (da) 2002-06-13 2009-10-05 Merck Patent Gmbh Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation
AU2003280505B2 (en) 2002-06-26 2009-01-15 Syncore Biotechnology Co., Ltd Method of producing a cationic liposomal preparation comprising a lipophilic compound
WO2004002453A1 (fr) * 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Appareil liposomal et procedes de fabrication
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
EP1519745B1 (fr) * 2002-07-05 2006-12-20 Lipoxen Technologies Limited Procede permettant d'augmenter une reponse immunitaire de vaccination par un acide nucleique
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CA2542217C (fr) 2003-10-15 2018-03-27 Medigene Ag Procede d'administration de liposomes cationiques comprenant un medicament actif
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP2008509890A (ja) * 2004-08-05 2008-04-03 ベイラー・リサーチ・インスチチユート 遺伝子または薬剤送達系
JP2008520600A (ja) * 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
EP1674081A1 (fr) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Préparation de nano-particules à bases lipides en utilisant une centrifuge duale et asymétrique
MX2007008010A (es) 2004-12-29 2007-09-07 Mannkind Corp Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP4332227A1 (fr) 2005-08-23 2024-03-06 The Trustees of the University of Pennsylvania Arn contenant des nucléosides modifiées et leurs procédés d'utilisation
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (fr) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
WO2007107304A2 (fr) * 2006-03-17 2007-09-27 Novosom Ag Procédé efficace de chargement de liposomes amphotères avec des substances actives d'acides nucléiques
US20120021042A1 (en) * 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
AU2007220042A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
WO2008085562A2 (fr) 2006-09-20 2008-07-17 The Johns Hopkins University Thérapie combinatoire contre le cancer et les maladies infectieuses utilisant un vaccin et des anti-b7-h1
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
RU2478400C2 (ru) 2006-12-27 2013-04-10 Эмори Юниверсити Композиции и способы лечения инфекций и опухолей
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2008257419B2 (en) * 2007-05-23 2013-10-24 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
EP2060583A1 (fr) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
PL2276486T3 (pl) 2008-03-24 2014-04-30 4Sc Discovery Gmbh Nowe podstawione imidazochinoliny
CN110075113A (zh) 2008-04-17 2019-08-02 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2406376A1 (fr) * 2009-03-12 2012-01-18 Alnylam Pharmaceuticals, Inc. COMPOSITIONS FORMULÉES DE LIPIDES ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE GÈNES DE Eg5 ET DE VEGF
WO2011012316A2 (fr) 2009-07-31 2011-02-03 Ludwig-Maximilians-Universität Arn ayant une combinaison de nucléotides non modifiés et modifiés pour l'expression protéique
EP2544533A4 (fr) * 2010-03-12 2014-07-09 Univ California Libération déclenchée de la cargaison de liposomes nanoparticulaires stabilisés
WO2013040142A2 (fr) 2011-09-16 2013-03-21 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
CN103180730B (zh) 2010-05-14 2016-03-02 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
RU2707251C2 (ru) 2011-10-03 2019-11-25 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012356239B2 (en) * 2011-11-04 2016-09-22 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013106496A1 (fr) 2012-01-10 2013-07-18 modeRNA Therapeutics Procédés et compositions destinés au ciblage d'agents dans et à travers la barrière hémato-encéphalique
WO2013124701A2 (fr) 2012-02-20 2013-08-29 Universita' Degli Studi Di Milano Nouveaux composés mimétiques de smac de type homodimère et hétérodimère à titre d'inducteurs d'apoptose
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
EP2833892A4 (fr) 2012-04-02 2016-07-20 Moderna Therapeutics Inc Polynucléotides modifiés destinés à la production de protéines et de peptides associés à l'oncologie
EP2872653B1 (fr) 2012-07-12 2019-03-13 Persimmune, Inc. Vaccins anticancéreux personnalisés et thérapies cellulaires immunitaires adoptives
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
KR102596302B1 (ko) 2012-11-01 2023-11-01 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014159813A1 (fr) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
WO2014152211A1 (fr) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
WO2014160243A1 (fr) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification et évaluation de la pureté de molécules d'arn synthétisées comprenant des nucléosides modifiés
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014144767A1 (fr) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Purification d'arnm par échange d'ions
WO2014150179A1 (fr) * 2013-03-15 2014-09-25 Rush University Medical Center Exotoxines de pseudomonas destinées au traitement du cancer
WO2014152030A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Elimination de fragments d'adn dans des procédés de production d'arnm
WO2014152027A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Procédés de fabrication pour la production de transcrits d'arn
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014168874A2 (fr) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions et procédés s'appliquant à des vaccins personnalisés contre les néoplasies
WO2015014375A1 (fr) 2013-07-30 2015-02-05 Biontech Ag Antigènes de tumeur pour déterminer une thérapie anticancéreuse
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3043826A4 (fr) 2013-09-13 2017-05-24 Moderna Therapeutics, Inc. Compositions polynucléotididiques contenant des acides aminés
AU2013401479B2 (en) 2013-09-26 2019-04-04 BioNTech SE Particles comprising a shell with RNA
WO2015051169A2 (fr) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Molécules de polynucléotides et leurs utilisations
US20160264614A1 (en) 2013-10-02 2016-09-15 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (fr) 2013-10-25 2015-04-30 Biontech Ag Méthode et kit pour déterminer si un patient présente une réponse immunitaire
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
EP3053585A1 (fr) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Molécules d'acide nucléique alternatives et utilisations associées
CA2938700A1 (fr) 2014-02-05 2015-08-13 Biontech Ag Canule, dispositif d'injection ou perfusion, et procedes d'utilisation de canule ou de dispositif d'injection ou perfusion
BR112016024644A2 (pt) 2014-04-23 2017-10-10 Modernatx Inc vacinas de ácido nucleico
WO2015172843A1 (fr) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Méthodes et kits destinés au diagnostic du cancer
WO2016045732A1 (fr) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Formulations stables de lipides et de liposomes
WO2016062323A1 (fr) 2014-10-20 2016-04-28 Biontech Ag Methodes et compositions de diagnostic et de traitement du cancer
PL3708668T3 (pl) 2014-12-12 2022-12-05 Curevac Ag Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka
KR102580696B1 (ko) 2014-12-30 2023-09-19 큐어백 에스이 신규 인공 핵산 분자
WO2016155809A1 (fr) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Formulations de particules lipidiques permettant la délivrance à une cellule cible d'arn et de composés hydrosolubles thérapeutiquement efficaces

Also Published As

Publication number Publication date
BR112017005821B1 (pt) 2022-06-14
IL291055B1 (en) 2023-01-01
CN107072945A (zh) 2017-08-18
KR102264820B1 (ko) 2021-06-14
IL250991B (en) 2022-04-01
RU2017113970A (ru) 2018-10-25
SG11201702182YA (en) 2017-04-27
JP2017532322A (ja) 2017-11-02
US20170273907A1 (en) 2017-09-28
CA2960934A1 (fr) 2016-03-31
CN107072945B (zh) 2021-04-06
IL291055B2 (en) 2023-05-01
MY184381A (en) 2021-04-01
US20220023212A1 (en) 2022-01-27
KR20170063780A (ko) 2017-06-08
AU2015320980A1 (en) 2017-04-06
JP6703982B2 (ja) 2020-06-03
IL250991A0 (en) 2017-04-30
NZ730368A (en) 2024-02-23
CA2960934C (fr) 2021-08-24
US11173120B2 (en) 2021-11-16
EP3197433A1 (fr) 2017-08-02
IL291055A (en) 2022-05-01
BR112017005821A2 (pt) 2017-12-12
MX2017003794A (es) 2017-07-07
ZA201701670B (en) 2021-05-26
RU2017113970A3 (fr) 2019-04-15
RU2738060C2 (ru) 2020-12-07
WO2016046060A1 (fr) 2016-03-31
AU2015320980B2 (en) 2021-02-18
WO2016045732A1 (fr) 2016-03-31

Similar Documents

Publication Publication Date Title
MA40627A (fr) Formulations stables de lipides et de liposomes
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
BR112017011215A2 (pt) partículas de distribuição de pró-flavorizante
BR112018012145A2 (pt) partículas de entrega de pró-sabor
MX2020010026A (es) Formulaciones de anticuerpos anti-pdl1.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
WO2014179748A3 (fr) Compositions et procédés d'obtention de lipide fongique
MX2017009937A (es) Cepas fungicas y metodos de uso.
MX2016016123A (es) Microemulsiones y sus usos.
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
TWD180369S (zh) 無儲水桶式逆滲透淨水器
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
MX2016003207A (es) Composiciones que comprenden colina y derivados de esta, usos de las composiciones y procesos para su preparacion.
EA201591725A1 (ru) Твердые липидные наночастицы (ii)
MX2020002793A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
MX2017005700A (es) Composiciones de microesferas de gas encapsuladas en lipidos y metodos relacionados.
EA201500927A1 (ru) Твердые липидные наночастицы (i)
NZ721832A (en) Solid forms of tenofovir
MX2016009229A (es) Formulacion de sales de rehidratacion liposomal.